DNTH

Dianthus Therapeutics, Inc. (DNTH) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation complement therapeutics for severe autoimmune and inflammatory diseases. The company's lead product candidate is claseprubart (formerly DNTH103), a monoclonal antibody targeting the active form of the C1s complement protein. The company operates as a single segment and has not yet generated revenue from product sales.

Key Financial Metrics

Note: Cash, cash equivalents, and investments as of June 30, 2025, totaled approximately $309.1 million ($13.2M cash + $244.2M short-term investments + $51.7M long-term investments).

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased significantly from $1.9 million in Q2 2024 to $0.2 million in Q2 2025. This was driven by the cessation of related-party license revenue from Zenas BioPharma (now Tenacia) as the company transitioned to a new agreement structure. YTD revenue also declined due to lower reimbursable costs associated with clinical trials.
• Increased Operating Expenses: Operating expenses rose by $11.1 million in Q2 2025 compared to Q2 2024.
  • R&D Expenses: Increased by $8.2 million (Q2) and $22.1 million (YTD), primarily due to higher external costs for clinical operations and CMC activities for claseprubart's Phase 2 and Phase 3 trials, as well as increased internal personnel costs.
  • G&A Expenses: Increased by $2.9 million (Q2) and $4.6 million (YTD), driven by higher stock-based compensation and personnel costs.
• Net Loss Expansion: Net loss widened to $31.6 million in Q2 2025 from $17.6 million in Q2 2024, reflecting the revenue decline and increased operational burn rate.
• Investment Income: Interest and investment income decreased to $3.4 million in Q2 2025 from $4.7 million in Q2 2024, attributed to lower average cash and investment balances in the current period compared to the prior year.

Guidance, Outlook, and Risks

• Clinical Pipeline:
  • MAGIC (gMG): Enrollment completed in May 2025 with 65 patients; top-line results expected in September 2025.
  • CAPTIVATE (CIDP): Phase 3 trial ongoing; interim responder analysis expected in H2 2026.
  • MOMENTUM (MMN): Phase 2 trial ongoing; top-line results expected in H2 2026.
• Liquidity Outlook: Management believes existing cash, cash equivalents, and investments ($309.1 million) are sufficient to fund operations into the second half of 2027. The company has an At-The-Market (ATM) offering program with $160.8 million of remaining capacity.
• Risks:
  • Substantial capital requirements and reliance on external financing.
  • Uncertainty regarding clinical trial outcomes and regulatory approval.
  • Dependence on third-party CROs and CDMOs.
  • Macroeconomic factors including inflation, interest rates, and geopolitical instability.
• Unusual Items: The company recognized $1.0 million in milestone revenue under the Tenacia Agreements during the six months ended June 30, 2025. Zenas BioPharma is no longer considered a related party as of May 2025.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $309.1 million cash position against the projected burn rate to confirm the "second half of 2027" liquidity timeline.
• Clinical Milestones: Monitor the September 2025 top-line data release for the MAGIC trial (gMG) as a critical value inflection point.
• Revenue Recognition: Review the accounting treatment of the Tenacia license agreement milestones and cost reimbursements to understand future revenue visibility.
• ATM Utilization: Track the usage of the remaining $160.8 million ATM capacity and any potential dilution from future equity raises.
• Expense Trajectory: Assess the sustainability of the increasing R&D burn rate ($53.3M YTD 2025) relative to clinical progress.